Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 20/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL843663 | 1.00 | CETP (0.60) | CETPKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL842926 | 1.00 | CETP (0.60) | CETPKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL843664 | 1.00 | CETP (0.60) | CETPKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL758500 | 1.00 | CETP (0.60) | CETPKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL758499 | 1.00 | CETP (0.60) | CETPKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL758601 | 1.00 | CETP (0.60) | CETPKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL757689 | 0.90 | CETP (0.69) | CETPKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL760872 | 0.90 | CETP (0.59) | CETPKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL760873 | 0.90 | CETP (0.59) | CETPKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL757370 | 0.90 | CETP (0.69) | CETPKCNH2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951690-B1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-28 | — | — | EP | disclosed |
| US-7652023-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CETP 1/4885KCNH2 2789/4885CYP1A2 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.